Navigation Links
Onyx Pharmaceuticals Announces First Quarter 2008 Financial Results Teleconference and Webcast
Date:4/29/2008

EMERYVILLE, Calif., April 29 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will webcast a teleconference with management to discuss first quarter 2008 financial results and provide a general business overview on Tuesday, May 6, 2008, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Financial results for the first quarter ended March 31, 2008 will be released earlier that day.

Interested parties may access a live webcast of the presentation on our website at: http://www.onyx-pharm.com/wt/page/event_calendar or by dialing 630-691-2760 and using the passcode 21488196. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 21488196 approximately one hour after the teleconference concludes. The replay will be available through June 6, 2008.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated(TM). The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R), a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer, and other cancers. For more information about Onyx, visit the company's website at http://www.onyx-pharm.com.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Core Informatics Delivers Enterprise Core LIMS Installation to BioRelix Pharmaceuticals
2. Syndexa Pharmaceuticals Corporation and ChemDiv, Inc. Announce Discovery Collaboration
3. Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing
4. Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
5. Keryx Biopharmaceuticals Receives Nasdaq Notification
6. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
7. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition
9. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
10. New Fragment-based Drug Discovery Platform Announced Between IOTA Pharmaceuticals Ltd, Cambridge (UK), and Beactica AB, Uppsala (Sweden)
11. MacroChem Acquires Virium Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 21, 2015  Prima Biomed Ltd. (NASDAQ: PBMD ... to become a leader in the development of immunotherapeutic ... the final CVac data from the Phase II CAN-003 ... for a clinically meaningful improvement in Overall Survival ("OS") ... In the group of second remission patients ...
(Date:5/21/2015)... , May 21, 2015  The EveryLife ... Hatch (R-UT) and Amy Klobuchar ... Now Accelerating Cures & Treatments, or OPEN ACT. ... disease patient advocacy organizations, this bipartisan legislation promises ... affordable medicines to rare disease patients by incentivizing ...
(Date:5/21/2015)... Germany (PRWEB) May 21, 2015 ... that its manufacturing facility in Worms, Germany has ... an independent subsidiary of the International Pharmaceutical Excipient ... Grace facilities that produce its SYLOID® FP brand ... received GMP certification, following the Curtis Bay, Maryland ...
(Date:5/21/2015)... 21, 2015  CytRx Corporation (NASDAQ: CYTR ... in oncology, today announced positive updated results from ... for the treatment of unresectable glioblastoma multiforme (GBM), ... multisite trial is designed to investigate the preliminary ... tumors have progressed following prior treatment with surgery, ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
... 10 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... on endocrine therapy and oncology, today announced the opening ... with cetrorelix pamoate for the treatment of benign prostatic ... more than 20 million men in the U.S. alone. ...
... ATLANTA, Georgia, June 10 , ... Elsevier / MC Strategies, a pioneer in ... to announce that five,Clinical e-Learning courses were named as winners ... International,Academy of the Visual Arts (IAVA). With thousands of entries ...
... , Three-of-Four Patients Surveyed Experience Daily Pain From ... the European League Against Rheumatism Annual Congress of ... Results from the Rheumatoid Arthritis: Insights, Strategies ... rheumatoid arthritis (RA) patients throughout Europe and Canada ...
Cached Biology Technology:AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 3AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 4AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 5Elsevier / MC Strategies Online Courses Named in the 15th Annual Communicator Awards 2Elsevier / MC Strategies Online Courses Named in the 15th Annual Communicator Awards 3Elsevier / MC Strategies Online Courses Named in the 15th Annual Communicator Awards 4New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives 2New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives 3New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives 4New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives 5New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives 6
(Date:5/22/2015)... , May 22, 2015 According ... by Solution (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, ... (Government and Utilities, Consumer and Home) - Global Forecast ... grow from $2.77 Billion in 2015 to $6.19 Billion ... Browse 79 market data Tables and   43 ...
(Date:5/21/2015)... -- The Sync Project™ , a global collaboration ... announced a collaborative partnership with Berklee,s Institute for ... collaboration on original research, joint course development and an ... The Sync Project and BerkleeICE are exploring the launch ... 2015-2016 academic year.  The course will ...
(Date:5/20/2015)... Conn. , May 20, 2015 NXT-ID, ... announces that its wholly owned subsidiary, 3D-ID LLC, a ... under Team Battelle for the biometrics technology portion of ... Suite Contract from the Department of the Army. ... recognition products developed for government, law enforcement and security ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... CHICAGO , Sept. 16, 2013  AUTOTESTCON –  Marvin ... Systems ), a trusted provider of innovative test solutions ... company,s involvement in AUTOTESTCON 2013 . The 49th ... Chicago, Illinois for ATE leaders ...
... A new understanding of the essential role of gut microbes ... with some of the more significant health problems facing people ... a new analysis. Problems ranging from autoimmune disease to ... to immune dysfunction that begins with a "failure to communicate" ...
... He heads the Institute for Diabetes and Obesity (IDO) ... director of the Helmholtz Diabetes Center (HDC). The Alexander ... Diseases at the Technische Universitt Mnchen (TUM). His research ... of fat and sugar metabolism, with the objective of ...
Cached Biology News:Marvin Test Solutions Featured at AUTOTESTCON 2013 with Leading Armament Experts and Test Systems 2Marvin Test Solutions Featured at AUTOTESTCON 2013 with Leading Armament Experts and Test Systems 3Gut microbes closely linked to proper immune function, other health issues 2Gut microbes closely linked to proper immune function, other health issues 3